Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of NSCLC

被引：38

作者：

Pallis, A. G. ^{[1
]}

Syrigos, K. N. ^{[2
]}

机构：

[1] Univ Gen Hosp Heraklion, Dept Med Oncol, Iraklion 71110, Crete, Greece

[2] Athens Sch Med, Oncol Unit GPP, Athens, Greece

来源：

LUNG CANCER | 2013年 / 80卷 / 02期

关键词：

NSCLC; Tyrosine kinase inhibitors; Erlotinib; Gefitinib; Targeted agents; Mutations; Resistance; CELL LUNG-CANCER; PHASE-III TRIAL; ERLOTINIB MAINTENANCE THERAPY; CLINICALLY SELECTED PATIENTS; PREVIOUSLY TREATED PATIENTS; VANDETANIB PLUS DOCETAXEL; GENE COPY NUMBER; ACQUIRED-RESISTANCE; DOUBLE-BLIND; OPEN-LABEL;

D O I：

10.1016/j.lungcan.2012.12.025

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Improvements in our understanding of the molecular biology of cancer have shifted management of lung cancer toward molecular-guided, individualized treatment. Development of epidermal growth factor receptor tyrosine kinase inhibitors, erlotinib and gefitinib, represent the best example of this approach. Erlotinib was tested as second/third line treatment in unselected population of patients and demonstrated a statistically significant prolongation of overall survival, while gefitinib was shown to be non-inferior to docetaxel as second line treatment. The discovery of EGFR activating mutations facilitated the selection of patients most likely to benefit from erlotinib/gefitinib. These drugs in patients with EGFR activating mutations offer an increased progression free survival and significantly higher response rates compared to chemotherapy. The purpose of this paper is to present the relevant clinical data, describe the predictive markers available for TKIs treatment in NSCLC, and describe the mechanisms associated with resistance to treatment with these agents. (C) 2013 Elsevier Ireland Ltd. All rights reserved.

引用

页码：120 / 130

页数：11

共 146 条

[1]

[Anonymous], J CLIN ONCOL

[2] Epidermal Growth Factor Receptor Mutations in Plasma DNA Samples Predict Tumor Response in Chinese Patients With Stages IIIB to IV Non-Small-Cell Lung Cancer [J].

Bai, Hua ;

Mao, Li ;

Wang, Hang Shu ;

Zhao, Jun ;

Yang, Lu ;

An, Tong Tong ;

Wang, Xin ;

Duan, Chun Jian ;

Wu, Na Mei ;

Guo, Zhi Qing ;

Liu, Yi Xu ;

Liu, Hong Ning ;

Wang, Ye Yu ;

Wang, Jie .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (16) :2653-2659

[3] Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor - Mutant lung adenocarcinomas with acquired resistance to kinase inhibitors [J].

Balak, Marissa N. ;

Gong, Yixuan ;

Riely, Gregory J. ;

Somwar, Romel ;

Li, Allan R. ;

Zakowski, Maureen F. ;

Chiang, Anne ;

Yang, Guangli ;

Ouerfelli, Ouathek ;

Kris, Mark G. ;

Ladanyi, Marc ;

Miller, Vincent A. ;

Pao, William .

CLINICAL CANCER RESEARCH, 2006, 12 (21) :6494-6501

[4] Acquired Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors Associated with a Novel T854A Mutation in a Patient with EGFR-Mutant Lung Adenocarcinoma [J].

Bean, James ;

Riely, Gregory J. ;

Balak, Marissa ;

Marks, Jenifer L. ;

Ladanyi, Marc ;

Miller, Vincent A. ;

Pao, William .

CLINICAL CANCER RESEARCH, 2008, 14 (22) :7519-7525

[5] MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib [J].

Bean, James ;

Brennan, Cameron ;

Shih, Jin-Yuan ;

Riely, Gregory ;

Viale, Agnes ;

Wang, Lu ;

Chitale, Dhananjay ;

Motoi, Noriko ;

Szoke, Janos ;

Broderick, Stephen ;

Balak, Marissa ;

Chang, Wen-Cheng ;

Yu, Chong-Jen ;

Gazdar, Adi ;

Pass, Harvey ;

Rusch, Valerie ;

Gerald, William ;

Huang, Shiu-Feng ;

Yang, Pan-Chyr ;

Miller, Vincent ;

Ladany, Marc ;

Yang, Chih-Hsin ;

Pao, William .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (52) :20932-20937

[6] Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment [J].

Becker, A. ;

Crombag, L. ;

Heideman, D. A. M. ;

Thunnissen, F. B. ;

van Wijk, A. W. ;

Postmus, P. E. ;

Smit, E. F. .

EUROPEAN JOURNAL OF CANCER, 2011, 47 (17) :2603-2606

[7] Met, metastasis, motility and more [J].

Birchmeier, C ;

Birchmeier, W ;

Gherardi, E ;

Vande Woude, GF .

NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2003, 4 (12) :915-925

[8] Efficacy and safety of PF299804 versus erlotinib (E): A global, randomized phase II trial in patients (pts) with advanced non-small cell lung cancer (NSCLC) after failure of chemotherapy (CT) [J].

Boyer, M. J. ;

Blackhall, F. H. ;

Park, K. ;

Barrios, C. H. ;

Krzakowski, M. J. ;

Taylor, I. ;

Liang, J. Q. ;

Denis, L. J. ;

O'Connell, J. P. ;

Ramalingam, S. S. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)

[9] Prospective Molecular Marker Analyses of EGFR and KRAS From a Randomized, Placebo-Controlled Study of Erlotinib Maintenance Therapy in Advanced Non-Small-Cell Lung Cancer [J].

Brugger, Wolfram ;

Triller, Nadja ;

Blasinska-Morawiec, Maria ;

Curescu, Stefan ;

Sakalauskas, Raimundas ;

Manikhas, Georgy Moiseevich ;

Mazieres, Julien ;

Whittom, Renaud ;

Ward, Carol ;

Mayne, Karen ;

Trunzer, Kerstin ;

Cappuzzo, Federico .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (31) :4113-4120

[10] PF-00299804 (PF299) patient (pt)-reported outcomes (PROs) and efficacy in adenocarcinoma (adeno) and nonadeno non-small cell lung cancer (NSCLC): A phase (P) II trial in advanced NSCLC after failure of chemotherapy (CT) and erlotinib (E) [J].

Campbell, A. ;

Reckamp, K. L. ;

Camidge, D. R. ;

Giaccone, G. ;

Gadgeel, S. M. ;

Khuri, F. R. ;

Engelman, J. A. ;

Denis, L. J. ;

O'Connell, J. P. ;

Janne, P. A. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)

← 1 2 3 4 5 6 7 8 9 10 →